Speciale Invest

Speciale Invest is a Chennai-based pre-seed and seed firm that has carved out a clear identity as one of the most credible deep-tech and hard-science investors in India. Founded in 2016, the team has invested across multiple funds into roughly forty companies spanning space tech, semiconductors, quantum computing, advanced air mobility, defense tech, and increasingly biotech, with portfolio names like Agnikul, ePlane, GalaxEye, CynLr, QNu Labs, and Fermbox Bio. The firm’s healthcare and biotech thesis is grounded in a specific argument: that the intersection of India’s biological talent, its cost structure, and a newly aligned policy environment creates a window for building biotech companies of global consequence from India, and they are willing to write the first institutional check, typically several crore at pre-seed, into founders pursuing that opportunity. Check sizes generally fall in the $250K to $1M range translated to USD, which matches a science-stage seed but does not stretch into Series A leadership. The right founder profile is a scientist-founder or engineer-founder with genuine technical depth in molecular biology, synthetic biology, AI-for-drug-discovery, advanced diagnostics, or medical devices, who needs patient capital and a partner comfortable with multi-year R&D timelines rather than SaaS-style monthly metrics. The wrong fit is a digital health workflow tool, a telehealth aggregator, or an Indian variant of a US consumer healthtech model; Speciale will route those founders to friends at Blume or Kae rather than waste anyone’s time. The right entry path is through the IIT Madras research and entrepreneurship community, through deep-tech accelerators like Catalyst at IIM-A or PiVeda, or through warm introductions from founders in the existing portfolio. The Speciale team also sources actively from academic conferences and labs, so a credible scientific advisor in your corner who knows them is gold. When pitching, lead with the science and the technical unfair advantage; the partners read papers and will engage seriously with the experimental plan. Then layer commercial logic on top, ideally with a clear regulatory and capital roadmap that acknowledges the realities of how long biotech takes to monetize. Caveats: Speciale writes early checks into capital-intensive science, which means founders should plan their bridge financing and Series A syndicate carefully, and they should expect Speciale to be helpful but not a balance-sheet for follow-on rounds beyond pro-rata.